What is the difference between HGH Fragment 176-191 and AOD-9604?

HGH Fragment 176-191 is the unmodified C-terminal peptide sequence of human growth hormone (amino acids 176–191). AOD-9604 is HGH Fragment 176-191 with a tyrosine added to the N-terminus for greater stability and longer half-life. Both target the same lipolytic mechanism via beta-3 adrenergic receptor activation in adipose tissue; AOD-9604 has the more formal research history including Phase II/IIb clinical trials and FDA GRAS status. HGH Frag 176-191 is the precursor compound with more community use history and lower cost.

Why is fasted cardio important with HGH Fragment 176-191?

The lipolytic mechanism of HGH Fragment 176-191 (HSL activation → free fatty acid release) is most active in the fasted state when insulin is low. Exercise increases fat oxidation simultaneously. The combination — fragment activates fat breakdown, exercise burns the released free fatty acids — is mechanistically synergistic. Without exercise, free fatty acids released by lipolysis may be re-esterified back into fat rather than oxidized. Fasted morning dosing with 20–30 minutes of cardio is the community's most consistently effective protocol.

COMPOUND LIBRARY·HGH FRAGMENT 176-191

COMPOUND PROFILE · PEPPERLEDGER

HGH Fragment 176-191 (HGH Frag)

Type

Synthetic peptide fragment of human growth hormone — the C-terminal region (amino acids 176–191) responsible for GH's lipolytic activity

Class

Lipolytic GH fragment — activates fat cell breakdown via the GH receptor's lipolytic domain without anabolic or IGF-1 effects

Administration

Subcutaneous injection · Intranasal (less bioavailable)

Half-life

~30 minutes

Most studied use

Targeted fat loss without GH's growth, IGF-1, or glucose effects

Regulatory status

Not FDA-approved · Research chemical · Precursor to AOD-9604 which received FDA GRAS status as a food ingredient

Human evidence

Limited — most human evidence is for AOD-9604 (the modified version). HGH Frag 176-191 itself has minimal human trial data.

Preclinical evidence

Strong — fat-specific lipolytic mechanism confirmed across multiple models

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is HGH Fragment 176-191?

HGH Fragment 176-191 is the C-terminal peptide sequence of human growth hormone that is responsible for GH's lipolytic (fat-burning) effects. The full GH molecule has multiple structural domains: some drive anabolic effects via IGF-1 (bone and muscle growth, glucose effects), while others drive lipolytic effects in adipose tissue. The fragment 176-191 isolates the lipolytic domain — the portion that activates fat breakdown without triggering the growth-promoting mechanisms.

The pharmacological concept is the same as AOD-9604: separate the fat-burning effects of GH from its growth-promoting effects. AOD-9604 is HGH Fragment 176-191 with a tyrosine added to the N-terminus for stability — making it slightly more potent and longer-lasting. Both target the same mechanism; AOD-9604 has the more formal research history including Phase II/IIb trials and FDA GRAS status. HGH Frag 176-191 is the precursor compound that's been in biohacker use longer and at lower cost.

The honest expectation: HGH Fragment 176-191 is a targeted metabolic tool for visceral and stubborn fat, not a primary weight loss compound. Users should not expect GLP-1 class weight loss. The compound's appeal is specificity — addressing fat metabolism directly in fat cells, without systemic metabolic complexity. Like AOD-9604, it does not elevate IGF-1, does not cause insulin resistance, and does not promote bone or soft tissue growth.

How it works

GH Lipolytic Domain — Isolated Function

Human growth hormone activates two functionally distinct downstream pathways: anabolic (via IGF-1 production and direct tissue growth) and lipolytic (via direct activation of hormone-sensitive lipase in adipose tissue). These pathways are mediated by different structural regions of the GH molecule. Fragment 176-191 contains the primary lipolytic domain — it activates fat cell breakdown without engaging the receptor interactions that drive IGF-1 production or anabolic signaling.

Beta-3 Adrenergic Receptor Activation

The primary lipolytic mechanism of HGH Fragment 176-191 involves activation of beta-3 adrenergic receptors in adipose tissue. Beta-3 AR activation stimulates hormone-sensitive lipase (HSL), which hydrolyzes stored triglycerides into free fatty acids and glycerol — the direct lipolytic event. This mechanism is well-characterized in rodent adipose tissue; the human translation depends on beta-3 AR expression in human fat, which is lower than in rodents.

No IGF-1, No Glucose Effects — The Clean Profile

HGH Fragment 176-191 does not significantly elevate IGF-1 levels, does not cause insulin resistance, and does not drive bone or soft tissue growth. These exclusions are mechanistically confirmed: the fragment lacks the structural regions that interact with GH-binding protein and the sites that drive IGF-1 axis signaling. For users specifically avoiding IGF-1-related risks or glucose effects, this clean metabolic profile is the primary appeal.

What the research shows

EVIDENCE NOTE — MOST HUMAN DATA IS FOR AOD-9604

Most human evidence in this mechanistic space comes from AOD-9604 trials (see AOD-9604 page). HGH Fragment 176-191 itself has limited published human data — the compound was largely superseded in formal research by the modified AOD-9604. The preclinical evidence for the mechanism is shared between both.

STUDYBiochemical and Molecular Biology International · 1993

Antilipogenic action of the synthetic hGH C-terminal 177-191 fragment

Wu Z et al.

The synthetic C-terminal hGH 177-191 fragment reproduced the antilipogenic action of intact growth hormone in rat adipose tissue — inhibiting fat synthesis — while showing no significant lipolytic (fat-breakdown) effect on its own. Early characterization of the fragment region that grounds both HGH Frag 176-191 and AOD-9604.

View on PubMed →

STUDYAmerican Journal of Physiology — Endocrinology and Metabolism · 2000

Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism

Heffernan MA, Jiang WJ, Thorburn AW, Ng FM

In obese mice (with confirmation in human adipose tissue), an orally administered synthetic hGH C-terminal fragment cut lipogenesis, boosted lipolysis, and raised energy expenditure and fat oxidation — slowing body-weight gain despite equal food intake. Preclinical basis for the fragment's fat-specific metabolic mechanism.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓Lipolytic mechanism in fat cells — beta-3 AR and HSL activation (preclinical confirmed)
✓No IGF-1 elevation or glucose effects — mechanistically confirmed
✓Fat-specific mechanism separable from GH's anabolic effects
✓Short plasma half-life (~30 min) — frequent dosing needed

?UNCERTAIN

?Human fat loss efficacy at injectable doses (no RCTs for HGH Frag 176-191 itself)
?Optimal dose and frequency for humans
?Whether human beta-3 AR expression is sufficient for meaningful response
?Comparative advantage over AOD-9604 (the more stable modified version)

What the community reports

—Gradual fat reduction — primarily visceral and stubborn fat; described as subtle rather than dramatic over 8–12 week protocols

—Most effective with fasted cardio — users who combine with fasted morning exercise consistently report better results; consistent with the lipolytic mechanism being enhanced in the fasted state

—No appetite suppression — distinct from GLP-1 class; caloric discipline remains fully on the user

—Clean side-effect profile — very few adverse effects reported; some injection site reactions

—AOD-9604 comparison: users who have tried both generally report similar effects; AOD-9604 is slightly more expensive; HGH Frag is the budget version

—Stacked with GH secretagogues: some users run HGH Frag alongside CJC-1295 + ipamorelin for both GH elevation and direct lipolytic effects simultaneously

Common misconceptions

"HGH Fragment 176-191 is the same as AOD-9604."

REALITY

Close but not identical. AOD-9604 is HGH Frag 176-191 with a tyrosine added to the N-terminus, providing greater stability and longer half-life. AOD-9604 has the formal clinical trial history (Phase II/IIb, FDA GRAS status). HGH Frag 176-191 is the unmodified fragment with more community use history but less formal research. Same mechanism, different molecules.

"HGH Fragment burns fat dramatically."

REALITY

The mechanism is real; the human effect size appears modest based on AOD-9604's Phase II/III data. Injectable HGH Frag may perform differently than oral doses tested in trials. Community experience suggests modest, consistent fat reduction over weeks — not dramatic transformation. This is not GLP-1 class efficacy.

"This is a safer alternative to GH therapy."

REALITY

HGH Fragment 176-191 is not GH therapy — it targets only the lipolytic function of GH and does not produce GH's other benefits (IGF-1 elevation, anabolic effects, GH-specific metabolic improvements). It's a targeted fat-loss tool, not a safer form of GH replacement.

LIPOLYTIC PEPTIDE COMPARISON

HGH Frag 176-191: unmodified GH fragment, most community use history, lower cost. AOD-9604: modified version (+ tyrosine), more stable, formal clinical trial history, FDA GRAS status. Tesamorelin: FDA-approved GHRH analogue — visceral fat reduction via full GH axis. Semaglutide: GLP-1 class — dramatically more potent weight loss with established human safety.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI RESEARCHER PREVIEW

I want to run HGH Fragment 176-191 for fat loss. Should I use it instead of AOD-9604?

Good question — let me clarify the actual difference before you decide. HGH Fragment 176-191 and AOD-9604 are not the same compound, even though most people treat them interchangeably. HGH Frag 176-191 is the unmodified C-terminal GH fragment (amino acids 176–191). AOD-9604 is HGH Frag with a tyrosine added to the N-terminus — slightly more stable, longer half-life, and has the formal research history including Phase II/IIb clinical trials and FDA GRAS status as a food ingredient. Same mechanism, different molecules. If I had to pick between them: AOD-9604 has the formal evidence base. HGH Frag 176-191 has been in community use longer and is typically cheaper. If you're running either as a fat-loss tool, the protocol matters more than which one you choose. Key considerations: Fasted morning dosing is the most important variable — lipolysis is highest in the fasted state. Adding 20–30 minutes of cardio after dosing converts freed fatty acids into oxidized fuel rather than letting them be re-esterified. Neither compound suppresses appetite, so caloric discipline is entirely on you — this is not GLP-1 class. What's your primary fat loss goal — general visceral reduction, stubborn area targeting, or trying to avoid appetite suppression from other compounds?

CONTINUE IN THE APP

Open PepperLedger to track your HGH Fragment protocol →

Free to join. No credit card. Ask the Researcher about your lipolytic peptide stack once you're in.

Free to join · No credit card · 23-day Pro trial included

Authoritative sources

Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.

ClinicalTrials.gov · completed · NCT03865953
Oral LAT8881 (AOD-9604 / hGH fragment) in neuropathic pain
ClinicalTrials.gov · completed · NCT05298306
LAT8881 (AOD-9604) in lumbar radicular pain